GI ReFacto To Launch In 3rd Quarter; Bayer Predicts Kogenate FS In 2nd Half
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genetics Institute’s planned third-quarter launch of ReFacto means that two albumin-free recombinant factor VIII products could enter the market in close proximity.